What is Immusoft?
Immusoft Corporation is a biotechnology company focused on developing treatments for diseases through its proprietary Immune System Programming (ISP) platform. This innovative technology involves modifying a patient's own B cells to act as cellular factories, producing therapeutic gene-encoded medicines directly within the body. The ISP platform aims to offer a new paradigm in disease treatment by leveraging the patient's immune system for sustained therapeutic delivery.
How much funding has Immusoft raised?
Immusoft has raised a total of $33.3M across 5 funding rounds:
Private Equity
$2.4M
Series A
$2.7M
Series B
$20M
Debt
$150K
Other Financing Round
$8M
Private Equity (2014): $2.4M, investors not publicly disclosed
Series A (2016): $2.7M, investors not publicly disclosed
Series B (2019): $20M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Other Financing Round (2023): $8M backed by The California Institute for Regenerative Medicine
Key Investors in Immusoft
The California Institute for Regenerative Medicine
The California Institute for Regenerative Medicine (CIRM) is a state agency dedicated to advancing stem cell, regenerative medicine, and gene therapy research. CIRM funds a broad spectrum of research from early discovery to clinical trials, with a focus on developing transformative treatments for serious diseases and ensuring equitable access to these therapies.
What's next for Immusoft?
With the recent major strategic investment, Immusoft is poised to accelerate the development and potential commercialization of its ISP technology. The substantial capital infusion, particularly from entities like The California Institute for Regenerative Medicine, indicates strong confidence in the company's therapeutic approach. This backing will likely support further clinical trials, platform optimization, and expansion of its research and development capabilities, moving Immusoft closer to addressing unmet medical needs.
See full Immusoft company page
